DUFADIL-5 – Tofacitinib 5 mg Tablets
DUFADIL-5 contains Tofacitinib 5 mg, a Janus kinase (JAK) inhibitor used for the management of certain autoimmune and inflammatory conditions. It works by targeting specific intracellular signaling pathways involved in immune system activity and inflammation.
Tofacitinib may be prescribed for eligible patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and polyarticular juvenile idiopathic arthritis, according to approved indications and prescribing guidelines. By modulating cytokine signaling, it helps control inflammatory processes and may improve symptoms, joint function, and overall disease management.
DUFADIL-5 is designed for prescription-based treatment under the supervision of a qualified healthcare professional. The dosage and duration of therapy should be determined according to the patient’s condition, medical history, treatment response, and official prescribing information.
Tofacitinib may cause serious adverse effects, including severe infections, and requires appropriate patient assessment and regular monitoring. Healthcare professionals should evaluate infection risks, relevant contraindications, and potential drug interactions before starting treatment.
Key Features:
- Contains Tofacitinib 5 mg.
- Janus kinase (JAK) inhibitor.
- Used in selected autoimmune and inflammatory conditions.
- Requires medical supervision and appropriate safety monitoring.
Indications of DUFADIL-5 (Tofacitinib 5 mg Tablets)
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ulcerative Colitis
- Ankylosing Spondylitis
- Polyarticular Juvenile Idiopathic Arthritis
- Vitiligo
DUFADIL-5 represents a targeted therapeutic option for eligible patients requiring specialist-managed treatment of autoimmune and inflammatory diseases.
NOTES: For the use of Registered Medical Practitioner or a Hospital or Laboratory only
For more such product information and similar product category Miscellaneous
You can also contact us www.dakshpharma.com/contact-us
